Each tablet contains 12.5 mg of alomtriptan (Almotriptanum) in the form of almotriptan malate.
Acute treatment of headache in acute migraine attacks with or without aura. The medicinal product may only be used in patients with a history of migraine other than basilar, hemiplegic or ophthalmoplegic migraine.
NOMIGREN should only be used to treat an existing migraine attack, not to prevent migraine attacks or headaches. The drug can only be used in patients diagnosed with migraine.
Dose adults (ages 18 to 65)
The recommended dose is one tablet (12.5 mg). The tablet should be taken as soon as possible after a migraine attack starts. If the migraine attack persists, do not take more than one tablet during the same attack.
If the patient has another migraine attack within 24 hours, a second 12.5 mg tablet may be taken, provided there is at least a 2-hour interval between taking the first and second tablet.
The maximum daily dose is two tablets (25 mg) within 24 hours.
The tablet should be swallowed with a drink (e.g. water). The tablet can be taken with or without food.
The drug should be taken as soon as possible after the migraine attack started; however, it is also effective when taken at a later stage.
Hypersensitivity to the active substance or any of the excipients. As with other 5-HT1B/1D agonists, almotriptan should not be used in patients with symptoms or history of the following conditions: Ischemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal’s angina) or severe high blood pressure or uncontrolled mild or moderate high blood pressure. Use in patients with a history of a cerebrovascular accident (CVA) or transient ischemic attack (TIA). Peripheral vascular disease. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated. Use in patients with severe hepatic impairment.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
Each tablet contains 12.5 mg of alomtriptan (Almotriptanum) in the form of almotriptan malate.
Acute treatment of headache in acute migraine attacks with or without aura. The medicinal product may only be used in patients with a history of migraine other than basilar, hemiplegic or ophthalmoplegic migraine.
NOMIGREN should only be used to treat an existing migraine attack, not to prevent migraine attacks or headaches. The drug can only be used in patients diagnosed with migraine.
Dose adults (ages 18 to 65)
The recommended dose is one tablet (12.5 mg). The tablet should be taken as soon as possible after a migraine attack starts. If the migraine attack persists, do not take more than one tablet during the same attack.
If the patient has another migraine attack within 24 hours, a second 12.5 mg tablet may be taken, provided there is at least a 2-hour interval between taking the first and second tablet.
The maximum daily dose is two tablets (25 mg) within 24 hours.
The tablet should be swallowed with a drink (e.g. water). The tablet can be taken with or without food.
The drug should be taken as soon as possible after the migraine attack started; however, it is also effective when taken at a later stage.
Hypersensitivity to the active substance or any of the excipients. As with other 5-HT1B/1D agonists, almotriptan should not be used in patients with symptoms or history of the following conditions: Ischemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal’s angina) or severe high blood pressure or uncontrolled mild or moderate high blood pressure. Use in patients with a history of a cerebrovascular accident (CVA) or transient ischemic attack (TIA). Peripheral vascular disease. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated. Use in patients with severe hepatic impairment.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
